Klivira
Request demo

Streamlining Medicare Epclusa Prior Authorization

For healthcare organizations managing Hepatitis C treatment, efficient Medicare Epclusa prior authorization is critical for patient access and revenue integrity. Klivira automates the complex PA process across Medicare segments.

Prior authorization for high-cost specialty drugs like Epclusa can be a significant administrative burden, impacting patient care timelines and staff productivity. Understanding the nuances of Medicare's various PA requirements, from Original Medicare to Medicare Advantage plans, is essential for timely approvals and reduced denials.

Epclusa: A High-Volume Prior Authorization Target

Epclusa (sofosbuvir/velpatasvir) is a direct-acting antiviral medication used to treat chronic Hepatitis C virus (HCV) infection. As a high-cost specialty medication, Epclusa frequently requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans to ensure medical necessity and adherence to clinical criteria. Efficient management of this PA process is paramount for patient access.

Navigating Medicare Prior Authorization Channels for Epclusa

Medicare's prior authorization landscape is segmented. For Original Medicare (Part A and B), the scope of services requiring PA is limited, with submissions routing through specific Medicare Administrative Contractors (MACs). In contrast, Medicare Part D plans, administered by private insurers, and Medicare Advantage (MA) plans, have broader PA requirements, including those for pharmacy benefits like Epclusa.

Key MACs for Original Medicare PA Submissions

  • Noridian Healthcare Solutions
  • NGS Medicare
  • WPS GHA
  • Palmetto GBA
  • First Coast Service Options (FCSO)
  • Novitas Solutions

Policy Adherence: NCDs, LCDs, and Part D Formularies

For Original Medicare, prior authorization decisions are guided by National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by the responsible MAC for each jurisdiction. For Epclusa under Medicare Part D, PA is determined by CMS-approved plan formularies and step-therapy protocols, often managed by Pharmacy Benefit Managers (PBMs). Precise citation of the applicable NCD number, LCD ID, or formulary criteria is critical.

Klivira's Approach to Medicare Epclusa PA Automation

Klivira integrates with EMRs via SMART on FHIR and other APIs to automate the prior authorization workflow for Epclusa across Medicare. Our platform routes submissions through the correct channels—whether to a specific MAC for Original Medicare (where PA applies) or directly to Part D and Medicare Advantage plans. We incorporate NCD/LCD-aware policy logic and support electronic prior authorization (ePA) standards like X12 278 and NCPDP SCRIPT to streamline the process.

Turnaround Times and Regulatory Considerations

While CMS-0057-F has expanded applicability for prior authorization turnaround times, its direct impact on Traditional Medicare is limited, primarily affecting Medicare Advantage, Medicaid managed care, and CHIP. For Epclusa, adherence to the specific timeframes documented per Medicare program and plan type is crucial. Klivira helps track and manage these timelines to minimize delays in patient care.

Frequently asked questions

Does Original Medicare directly cover Epclusa with prior authorization?

Original Medicare (Parts A and B) generally has limited prior authorization scope. Epclusa, as a prescription drug, is primarily covered under Medicare Part D plans, which are administered by private insurers and have their own PA requirements, including step therapy and formulary restrictions.

How do Medicare Part D plans determine Epclusa prior authorization?

Medicare Part D plans utilize CMS-approved formularies, which often include step therapy requirements and quantity limits for specialty drugs like Epclusa. Prior authorization requests are typically submitted electronically via ePA or through payer portals, adjudicated based on the plan's medical necessity criteria.

What role do NCDs and LCDs play in Epclusa prior authorization under Medicare?

National Coverage Determinations (NCDs) from CMS and Local Coverage Determinations (LCDs) from MACs define medical necessity criteria for services covered by Original Medicare. While Epclusa is primarily a Part D drug, these policies can inform coverage decisions if the drug is administered in a Part B setting or if related services require PA.

Which submission channels does Klivira use for Medicare Epclusa PA?

Klivira leverages multiple submission channels. For any applicable Original Medicare Part A/B services, we route through the responsible MAC's portal. For Medicare Part D and Medicare Advantage plans, we utilize direct API integrations, payer portals, and ePA standards (X12 278, NCPDP SCRIPT) to submit Epclusa prior authorization requests.

How does Klivira help with Epclusa prior authorization denials under Medicare?

Klivira streamlines the initial submission process to reduce denials by ensuring requests are complete and adhere to payer-specific criteria, NCDs, and LCDs. In the event of a denial, our platform facilitates efficient appeals management by organizing documentation and tracking communication, though specific appeal pathways vary by Medicare segment and plan.

Related coverage

Other epclusa prior authorization by payer

Other epclusa prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo